• Please log in or register to access this feature.

Original Article

You have full text access to this OnlineOpen article

Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer

Interim analysis of a prospective randomized noninferiority trial

  1. Xiao Hu MD1,†,
  2. Yong Bao MD1,†,
  3. Li Zhang MD2,†,
  4. Ying Guo MD3,
  5. Yuan Yuan Chen MD1,
  6. Kai Xin Li MD4,
  7. Wei Hua Wang MD5,
  8. Yuan Liu MD6,
  9. Han He MD7,
  10. Ming Chen MD1,*

Article first published online: 19 MAY 2011

DOI: 10.1002/cncr.26119

Issue

Cancer

Cancer

Volume 118, Issue 1, pages 278–287, 1 January 2012

Additional Information

How to Cite

Hu, X., Bao, Y., Zhang, L., Guo, Y., Chen, Y. Y., Li, K. X., Wang, W. H., Liu, Y., He, H. and Chen, M. (2012), Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer. Cancer, 118: 278–287. doi: 10.1002/cncr.26119

Author Information

  1. 1

    Department of Radiation Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, People's Republic of China

  2. 2

    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, People's Republic of China

  3. 3

    Good Clinical Practice, State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat Sen University, Guangzhou, People's Republic of China

  4. 4

    Department of Radiation Oncology, People's Liberation Army 180 Hospital, Quanzhou, People's Republic of China

  5. 5

    Radiation Therapy Center, Kiang Wu Hospital, Macau, People's Republic of China

  6. 6

    Department of Radiation Oncology, Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou, People's Republic of China

  7. 7

    Department of Radiation Oncology, The First People's Hospital of Foshan City, Foshan, People's Republic of China

  1. †

    The first 3 authors contributed equally to this article.

*Department of Radiation Oncology, Cancer Center, Sun Yat Sen University, 651 Dongfeng Rd E, Guangzhou 510060, People's Republic of China

  1. †

    The first 3 authors contributed equally to this article.

Publication History

  1. Issue published online: 16 DEC 2011
  2. Article first published online: 19 MAY 2011
  3. Manuscript Revised: 15 FEB 2011
  4. Manuscript Accepted: 15 FEB 2011
  5. Manuscript Received: 5 NOV 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (198K)

REFERENCES

  • 1
    Faivre-Finn C, West C, Lorigan P, et al. Thoracic radiation radiotherapy for limited-stage small-cell lung cancer: controversies and future developments. Clin Oncol (R Coll Radiol). 2005; 17: 591-598.
  • 2
    Pignon JP, Arriagada R, Idhe D, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992; 327: 1618-1622.
  • 3
    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell lung cancer. A meta-analysis. J Clin Oncol. 1992; 10: 890-895.
  • 4
    Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999; 341: 476-484.
  • 5
    Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002; 20: 4665-4672.
  • 6
    Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999; 340: 265-271.
  • 7
    Schild SE, Bonner JA, Hillman S, et al. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol. 2007; 25: 3124-3129.
  • 8
    Baas P, Belderbos JS, Senan S, et al. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. Br J Cancer. 2006; 94: 625-;630.
  • 9
    Spiro SG, James LE, Rudd RM, et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol. 2006; 24: 3823-3830.
  • 10
    Chen GY, Jiang GL, Wang LJ, et al. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial. Int J Radiat Oncol Biol Phys. 2005; 61: 70-75.
  • 11
    Bogart JA, Herndon JE 2nd, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004; 59: 460-468.
  • 12
    Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002; 20: 3054-3060.
  • 13
    Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001; 12: 1231-1238.
  • 14
    Jeremic B, Shibamoto Y, Acimovic L, et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol. 1997; 15: 893-900.
  • 15
    Videtic GM, Belderbos JS, Spring Kong FM, et al. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). Int J Radiat Oncol Biol Phys. 2008; 72: 327-334.
  • 16
    Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep (part 3). 1973; 4: 31-42.
  • 17
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31: 1341-1346.
  • 18
    Socinski MA, Bogart JA. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol. 2007; 25: 4137-4145.
  • 19
    Kies MS, Mira JG, Crowley JJ, et al. Multimodal therapy for limited small-cell lung cancer. A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group study. J Clin Oncol. 1987; 5: 592-600.
  • 20
    De Ruysscher D, Bremer RH, Koppe F, et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol. 2006; 80: 307-312.
  • 21
    Perez CA, Krauss S, Bartolucci AA, et al. Thoracic and elective brain irradiation with concomitant or delayed multiagent chemotherapy in the treatment of localized small cell carcinoma of the lung: a randomized prospective study by the Southeastern Cancer Study Group. Cancer. 1981; 47: 2407-2413.
    Direct Link:
  • 22
    White JE, Chen R, McCracken J, et al. The influence of radiation therapy quality control on survival, response and sites of relapse in oat cell carcinoma of the lung: preliminary report of a Southwest Oncology Group study. Cancer. 1982; 50: 1084-1090.
    Direct Link:
  • 23
    Liengswangwong V, Bonner JA, Shaw EG, et al. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and implications for thoracic radiotherapy. J Clin Oncol. 1994; 12: 496-502.
  • 24
    Brodin O, Rikner G, Steinholz L, et al. Local failure in patients treated with radiotherapy and multidrug chemotherapy for small cell lung cancer. Acta Oncol. 1990; 29: 739-746.
  • 25
    Azad A, Chionh F, Scott AM, et al. High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol. 2010; 12: 443-451.
  • 26
    van Loon J, Offermann C, Bosmans G, et al. 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. Radiother Oncol. 2008; 87: 49-54.
  • 27
    Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007; 18: 338-345.
  • 28
    Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol. 2004; 22: 3248-3254.
  • 29
    Kamel EM, Zwahlen D, Wyss MT, et al. Whole-body F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med. 2003; 44: 1911-1917.
  • 30
    Vinjamuri M, Craig M, Campbell-Fontaine A, et al. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer. 2008; 9: 30-34.
  • 31
    van Loon J, De Ruysscher D, Wanders R, et al. Selective nodal irradiation on basis of FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2010; 77: 329-336.
  • 32
    van Overhagen H, Brakel K, Heijenbrok MW, et al. Metastases in supraclavicular lymph nodes in lung cancer: assessment with palpation, US, and CT. Radiology. 2004; 232: 75-80.
  • 33
    Zhao L, Chen M, Ten Haken R, et al. Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol. 2007; 82: 153-159.
  • 34
    Chen M, Hayman JA, Ten Haken RK, Tatro D, Fernando S, Kong FM. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation? Int J Radiat Oncol Biol Phys. 2006; 64: 120-126.
  • 35
    Rosenzweig KE, Sim SE, Mychalczak B, Braban LE, Schindelheim R, Leibel SA. Elective nodal irradiation in the treatment of non-small-cell lung cancer with 3-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2001; 50: 681-685.
  • 36
    Komaki R, Swann RS, Ettinger DS, et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys. 2005; 62: 342-350.
  • 37
    Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide. http://www.clinicaltrials.gov/ct2/show/NCT00632853. Accessed January 1, 2010.
  • 38
    Cisplatin, Etoposide, and Two Different Schedules of Radiation Therapy in Treating Patients With Limited Stage Small Cell Lung Cancer. http://www.clinicaltrials.gov/ct2/show/NCT00433563. Accessed January 1, 2010.
  • 39
    Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004; 22: 4837-4845.
  • 40
    De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol. 2006; 24: 1057-1063.
View Full Article (HTML) Get PDF (198K)